Eyeganics Organic Tears, the Only USDA-Certified Organic Lubricant Eye Drop, Now Available through NovaBay Pharmaceuticals’ Avenova.com and Physician-Dispensed Channel
March 14 2023 - 6:50AM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces a
partnership with Eyeganics to sell OTC Organic Tears (0.2% organic
glycerin) on Avenova.com and through Avenova’s physician-dispensed
channel. Organic Tears has no additives or artificial chemicals and
is the only lubricant eye drop certified by the USDA as 100%
organic and preservative-free.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230314005317/en/
Eyeganics Organic Tears (Photo: Business
Wire)
Organic Tears are formulated using only three ingredients –
organic glycerin (oil from organic vegetables), salt and water –
and are extremely refreshing to dry eyes. A new technology allows
for each bottle to dispense more than 250 drops of Organic Tears,
providing a cost and convenience advantage over other
preservative-free artificial tears found in single-use vials. The
product is offered in the 10 ml size for $29.00.
“Dry eye is a multifaceted and complex condition that’s becoming
increasingly common. We’ve now added another high-quality,
scientifically formulated product to Avenova.com that further
reinforces our website as a one-stop designation for customers
seeking relief from the symptoms of dry eye,” said Justin Hall,
NovaBay CEO. “This product fills a need in our product assortment
by offering a preservative free dry eye drop. Our partnership with
Eyeganics is the first of what we hope will be other highly
effective ophthalmic products added to our distribution
channels.”
“As a practicing eye doctor, I talk to a lot of patients about
what eye drops they use,” said Eyeganics founder and CEO Dan
Friederich, OD, FAAO. “I developed this product with all natural
ingredients to address the needs of patients affected by some
chemicals that may be found in other artificial tears. I’m
delighted to partner on this opportunity and to associate Organic
Tears with the high-quality products available on Avenova.com.”
About NovaBay Pharmaceuticals, Inc.:
NovaBay Pharmaceuticals, Inc. develops and sells scientifically
created and clinically proven eyecare and skincare products.
NovaBay’s leading product, Avenova® Antimicrobial Lid & Lash
Solution, is often prescribed by eyecare professionals for
blepharitis and dry-eye disease and is also available directly to
eyecare consumers through online distribution channels such as
Amazon. DERMAdoctor® offers more than 30 OTC
dermatologist-developed skincare products through the DERMAdoctor
website, well-known traditional and digital beauty retailers, and
international distributors. NovaBay also manufactures and sells
effective, yet gentle and non-irritating wound care products. The
PhaseOne® brand is distributed through commercial partners in the
U.S. for professional use only, and the NeutroPhase® brand is
distributed in China by Pioneer Pharma (Hong Kong) Company Ltd.
NovaBay Pharmaceuticals Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release may be forward looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial
progress and future financial performance of NovaBay
Pharmaceuticals, Inc. This release contains forward-looking
statements that are based upon management’s current expectations,
assumptions, estimates, projections and beliefs. These statements
include, but are not limited to, statements regarding our business
strategies, current partnerships, marketing efforts, and any future
revenue that may result from such partnerships and related
marketing initiatives, as well as generally the Company’s expected
future financial results. These statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results or achievements to be materially different and
adverse from those expressed in or implied by the forward-looking
statements. Factors that might cause or contribute to such
differences include, but are not limited to, risks and
uncertainties relating to the size of the potential market for our
products, the possibility that the available market for the
Company’s products will not be as large as expected, the Company’s
products will not be able to penetrate one or more targeted
markets, and revenues will not be sufficient to meet the Company’s
cash needs. Other risks relating to NovaBay’s business, including
risks that could cause results to differ materially from those
projected in the forward-looking statements in this press release,
are detailed in NovaBay’s latest Form 10-Q/K filings and
Registration Statement on Form S-1 filing with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
Socialize and Stay Informed on
NovaBay’s Progress Like us on Facebook Follow us on
Twitter Connect with NovaBay on LinkedIn Visit NovaBay’s
Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com Avenova.com
DERMAdoctor Purchasing
Information For DERMAdoctor purchasing information:
Please call 877-337-6237 or email service@dermadoctor.com
DERMAdoctor.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230314005317/en/
NovaBay Contact Justin Hall
Chief Executive Officer and General Counsel 510-899-8800
jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2023 to Apr 2024